Immunomodulation Effects of Bryophyllum Pinnatum on Pregnant Pristane-Induced Lupus Mice Model

Nurdiana Nurdiana, Elvira Sari Dewi, Yuni Sari, Rahmawati Wahyuni, Aminah Maya, Nursari Abdul Syukur, Mirza Zaka Pratama, Wisnu Barlianto, Umi Kalsum, Kusworini Handono


Objective: To determine the effect of Bryophyllum pinnatum treatment in modulating immune response and the pregnancy outcomes of pregnant pristane-induced lupus mice model.

Methods: Sixteen Balb/c mice were intraperitoneally injected with single 0.5 cc pristane to induce lupus manifestations. After 12 weeks of injection, mice were mated and considered as gestational day 0 (GD0). Mice were divided into 4 groups based on the dosages of Bryophyllum pinnatum: control (no treatment), B1 (10.5 mg/kg), B2 (21 mg/kg), and B3 (42 mg/kg). The treatment was given orally every day started from GD9 until 9 days. At the end of the study, blood pressure and fetal size were measured. Serum anti-dsDNA and urine albumin levels were measured by ELISA. Spleen T helper (Th) and mature B cells percentages were measured by flow cytometry.

Results: Administration of Bryophyllum pinnatum reduced the percentages of Th1 (p=0.006), Th2 (p=0.005), Th17 (p=0.000), and mature B cells (p=0.007) in dose-dependent manner. B1 and B2 had significantly lower of systolic blood pressure compared to control (p=0.026 and p=0.022 respectively). Significantly lower of anti-dsDNA levels were found in B1 group compared to control (p=0.014). However, no significantly different of urine albumin levels were found between groups. Bryophyllum pinnatum also significantly increased the fetus body weight in dose-dependent manner (p=0.000).

Conclusion: Treatment of Bryophyllum pinnatum could improve the pregnancy outcome and modulate the immune response in pregnant pristane-induced lupus mice. Therefore, Bryophyllum pinnatum is a potential herb which can be developed as an immunosuppressive agent in the future.


Systemic lupus erythematosus; Bryophyllum pinnatum; pregnancy; T helper; mature B cells

Full Text:



Choi J, Kim ST, Craft J (2012): The pathogenesis of systemic lupus erythematosus—an update. Curr Opin Immunol 24(6): 651-657,

Ostensen M, Clowse M (2013): Pathogenesis of pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol 25(5): 591-596,

Stojan G, Baer AN (2014): Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 8(5): 439-453,

Tochihara M, Katsumata Y, Okamoto Y, Kawaguchi Y, Yamanaka H (2016): THU0342 Pregnancy outcome in japanese patients with systemic lupus erythematosus: a retrospective study of 134 pregnancies. Ann Rheum Dis 75(Suppl 2): 310-311,

Nili F, McLeod L, O’Connell C, Sutton E, McMillan D (2013): Maternal and neonatal outcomes in pregnancies complicated by systemic lupus erythematosus: a population-based study. J Obstet Gynaecol Can 35(4): 323-328,

Wallenius M, Salvesen KÅ, Daltveit AK, Skomsvoll JF (2014). Systemic lupus erythematosus and outcomes in first and subsequent births based on data from a national birth registry. Arthritis Care Res 66(11): 1718-1724,

Kalim H, Handono K, Pratama MZ, Fitria SN, Mahardika V (2015): Low birth weight and maternal and neonatal deaths are complications of systemic lupus erythematosus in pregnant pristane induced lupus mice. Arch Rheumatol 30(4): i-vii

Vachvanichsanong P, Dissaneewate P, McNeil E (2010): Twenty-two years' experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries? Arch Dis Child 96(1): 44-49,

Hoeltzenbein M, Elefant E, Vial T, et al (2012): Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Gen A 158(3), 588-596,

Skuladottir H, Wilcox AJ, Ma C, et al (2014): Corticosteroid use and risk of orofacial clefts. Birth Defects Research A Clin Mol Teratol 100(6), 499-506,

Ponticelli C, Moroni G (2015): Immunosuppression in pregnant women with systemic lupus erythematosus. Expert Rev Clin Immunol 11(5), 549-552,

Ostensen M, Lockshin M, Doria A, et al (2008): Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatol (Oxford) 47(Suppl 3): iii28-iii31.

Sangle SR, Lutalo PM, Davies RJ, Khamashta MA, D'Cruz DP (2013): B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun 43: 55-59,

Rossi‐Bergmann B, Costa SS, Borges MBS, Da Silva SA, Noleto GR, Souza MLM, Moraes VLG (1994): Immunosuppressive effect of the aqueous extract of Kalanchoe pinnata in mice. Phytother Res 8(7): 399-402,

Afzal M, Kazmi I, Khan R, Singh R, Chauhan M, Bisht T, Anwar F (2012): Bryophyllum pinnatum: a review. Int J Res Biol Sci 2(4): 143-149,

Akinsulire OR, Aibin IE, Adenipekun T, Adelowotan T, Odugbemi T (2007): In vitro antimicrobial activity of crude extracts from plants Bryophyllum pinnatum and Kalanchoe crenata. Afr J Tradit Complement Altern Med 4(3): 338-344,

Pal S, Chaudhuri AN (1991): Studies on the anti-ulcer activity of a Bryophyllum pinnatum leaf extract in experimental animals. J Ethnopharmacol 33(1): 97-102,

Ojewole JA (2005): Antinociceptive, anti-inflammatory and antidiabetic effects of Bryophyllum pinnatum (Crassulaceae) leaf aqueous extract. J Ethnopharmacol 99(1): 13-19,

Ojewole JA (2002): P-2: Antihypertensive properties of Bryophyllum pinnatum {(Lam) Oken} leaf extracts. Am J Hypertens 15(S3): 34A-34A,

Cruz EA, Reuter S, Martin H, et al (2012): Kalanchoe pinnata inhibits mast cell activation and prevents allergic airway disease. Phytomedicine 19(2): 115-121,

Almeida AP, Da Silva SAG, Souza MLM, Lima LMTRR, Rossi-Bergmann B, de Moraes VG, Costa SS (2000): Isolation and chemical analysis of a fatty acid fraction of Kalanchoe pinnata with a potent lymphocyte suppressive activity. Planta medica, 66(02: 134-137,

Cruz EA, Da-Silva SAG, Muzitano MF, Silva PMR, Costa SS, Rossi-Bergmann B (2008): Immunomodulatory pretreatment with Kalanchoe pinnata extract and its quercitrin flavonoid effectively protects mice against fatal anaphylactic shock. Int Immunopharmacol, 8(12): 1616-1621,

Iaccarino L, Ghirardello A, Zen M, Villalta D, Tincani A, Punzi L, Doria A (2012): Polarization of TH2 response is decreased during pregnancy in systemic lupus erythematosus. Reumatismo 64(5): 314-320,

Lissauer D, Goodyear O, Khanum R, Moss PA, Kilby MD (2014): Profile of maternal CD4 T-cell effector function during normal pregnancy and in women with a history of recurrent miscarriage. Clin Sci 126(5): 347-354,

Munoz‐Valle JF, Vazquez‐del Mercado M, Garcia‐Iglesias T, et al (2003): TH1/TH2 cytokine profile, metalloprotease‐9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol 131(2): 377-384,

Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD (2010): A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 5(11): 2060-2068,

Reinhard G, Noll A, Schlebusch H, Mallmann P, Ruecker AV (1998): Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptotic changes. Biochem Biophys Res Commun 245(3): 933-938,

Piccinni MP, Scaletti C, Maggi E, Romagnani S (2000): Role of hormone-controlled Th1-and Th2-type cytokines in successful pregnancy. J Neuroimmunol 109(1): 30-33.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.